HAYWARD, Calif., Feb. 24, 1999 (PRIMEZONE) -- RiboGene, Inc. (AMEX: RBO), announced that the Company is attending the Equities Magazine Conference in New York City, where it will present its recent accomplishments and future growth plans to members of the investment community.
The Emerging Growth Stock Day VII sponsored by the Equities Magazine is being held on February 25th at the Grand Hyatt Hotel, on 42nd Street at Grand Central in New York City. Mr. Charles Casamento, RiboGene Inc.'s Chairman, President and CEO, will make a formal presentation at 11:15 in the morning and will be speaking at the Parade of Presidents luncheon at 12:00 noon. He will also be available for private meetings with analysts, portfolio managers, media, and other members of the investment community throughout the day.
RiboGene's shares were recently recommended by the Special Situations Newsletter published by Robert J. Flaherty, who is also the publisher of the Equities Magazine, a 50 years old newsletter and magazine group specializing in publicly traded emerging growth companies.
RiboGene is a drug discovery company focused on the identification of novel lead compounds and the development of potential drug candidates for the treatment of infectious diseases. The company's drug discovery efforts target bacterial, fungal and viral infections, for which the efficacy of existing therapies is being threatened by the emergence of drug resistance or for which existing therapies have had limited effectiveness. Emitasol(r), a product to treat diabetic gastroporesis and delayed onset nausea and vomiting is in Phase III human clinical trials. It is partnered in North America with Roberts Pharmaceutical Co. (AMEX: RPC).
RiboGene also has strategic alliances with Dainippon Pharmaceutical Co., Ltd, ArQule Inc. (Nasdaq: ARQL), Pharmacopeia Inc. (Nasdaq: PCOP) and EnzyMed.
RiboGene went public on May 28, 1998 at $7.00 per share through Gruntal & Co., LLC, in a 2.3 million share IPO. Its common stock is traded on the American Stock Exchange under the symbol RBO.
Except for the historical information contained herein this press release contains forward-looking statements that involve risks and uncertainties, which are discussed in Registration Statement No. 333-38781, as filed by the company with the Securities and Exchange Commission. The risk factors and other information contained in such Registration Statement should be considered in evaluating the company's prospects and future financial performance.
For more information on RiboGene, please visit the Company's website at www.ribogene.com, or to attend the conference please contact Alan Stone & Company.